The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder

Charles L BowdenMood &amp; Anxiety Disorder Division, Department of Psychiatry, UT Health Science Center, San Antonio, TX, USAObjectives: This article addresses the clinical role for ziprasidone used adjunctively with a mood stabilizer in maintenance treatment of bipolar disorder. This revie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Charles L Bowden
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/e32bde48562f46e480afa256d20230f7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e32bde48562f46e480afa256d20230f7
record_format	dspace
spelling	oai:doaj.org-article:e32bde48562f46e480afa256d20230f72021-12-02T06:50:55ZThe role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder1176-63281178-2021https://doaj.org/article/e32bde48562f46e480afa256d20230f72011-03-01T00:00:00Zhttp://www.dovepress.com/the-role-of-ziprasidone-in-adjunctive-use-with-lithium-or-valproate-in-a6577https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Charles L BowdenMood &amp; Anxiety Disorder Division, Department of Psychiatry, UT Health Science Center, San Antonio, TX, USAObjectives: This article addresses the clinical role for ziprasidone used adjunctively with a mood stabilizer in maintenance treatment of bipolar disorder. This review also addresses the strengths and limitations of design features in adjunctive studies of second-generation antipsychotic drugs added to mood stabilizers.Methods: The principal study relevant to this review enrolled subjects who were &ge;18 years of age, experiencing a recent or current manic or mixed bipolar I episode, with at least moderately severe current manic symptoms. To meet criteria for randomization to 6 months maintenance treatment, patients had to have failed a short course of treatment with either lithium or valproate and achieved benefit with added ziprasidone for 8 consecutive weeks.Results: Time to intervention for a new mood episode as well as time to discontinuation for any reason was significantly longer with adjunctive ziprasidone treatment than with monotherapy treatment with mood stabilizer. Three dosages of ziprasidone augmentation were studied. Patients treated with 120 mg/day had better efficacy and overall outcomes than did patients who received 80 or 160 mg/day of ziprasidone.Conclusions: Good evidence exists that adjunctive ziprasidone will likely provide greater overall efficacy coupled with good tolerability for at least a 6-month period than a strategy of continued monotherapy with a mood stabilizer. Changes in open phases of maintenance studies to reduce study enrichment, in study endpoints, and in statistical approaches to analysis of data are warranted.Keywords: bipolar disorder, mania, maintenance, prophylaxis, ziprasidone, mood stabilizer Charles L BowdenDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss default, Pp 87-92 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Charles L Bowden The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
description	Charles L BowdenMood &amp; Anxiety Disorder Division, Department of Psychiatry, UT Health Science Center, San Antonio, TX, USAObjectives: This article addresses the clinical role for ziprasidone used adjunctively with a mood stabilizer in maintenance treatment of bipolar disorder. This review also addresses the strengths and limitations of design features in adjunctive studies of second-generation antipsychotic drugs added to mood stabilizers.Methods: The principal study relevant to this review enrolled subjects who were &ge;18 years of age, experiencing a recent or current manic or mixed bipolar I episode, with at least moderately severe current manic symptoms. To meet criteria for randomization to 6 months maintenance treatment, patients had to have failed a short course of treatment with either lithium or valproate and achieved benefit with added ziprasidone for 8 consecutive weeks.Results: Time to intervention for a new mood episode as well as time to discontinuation for any reason was significantly longer with adjunctive ziprasidone treatment than with monotherapy treatment with mood stabilizer. Three dosages of ziprasidone augmentation were studied. Patients treated with 120 mg/day had better efficacy and overall outcomes than did patients who received 80 or 160 mg/day of ziprasidone.Conclusions: Good evidence exists that adjunctive ziprasidone will likely provide greater overall efficacy coupled with good tolerability for at least a 6-month period than a strategy of continued monotherapy with a mood stabilizer. Changes in open phases of maintenance studies to reduce study enrichment, in study endpoints, and in statistical approaches to analysis of data are warranted.Keywords: bipolar disorder, mania, maintenance, prophylaxis, ziprasidone, mood stabilizer
format	article
author	Charles L Bowden
author_facet	Charles L Bowden
author_sort	Charles L Bowden
title	The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
title_short	The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
title_full	The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
title_fullStr	The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
title_full_unstemmed	The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
title_sort	role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/e32bde48562f46e480afa256d20230f7
work_keys_str_mv	AT charleslbowden theroleofziprasidoneinadjunctiveusewithlithiumorvalproateinmaintenancetreatmentofbipolardisorder AT charleslbowden roleofziprasidoneinadjunctiveusewithlithiumorvalproateinmaintenancetreatmentofbipolardisorder
_version_	1718399725413072896

The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder

Ejemplares similares